Obatoclax Mesylate (GX15-070)

Name: Obatoclax Mesylate (GX15-070)
Brand: Selleck Chemicals
SKU: S1057
Rating: 5 (80 reviews)

For research use only.

Catalog No.S1057

80 publications

Obatoclax Mesylate (GX15-070) Chemical Structure

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Selleck's Obatoclax Mesylate (GX15-070) has been cited by 80 publications

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cell, 2010, 20;142(4):590-600.

PubMed: 20723759 ( click the link to review the publication )

Biomaterials, 2020, 232:119709

PubMed: 31896513 ( click the link to review the publication )

Int J Mol Sci, 2020, 5;21(5) pii: E1773

PubMed: 32150830 ( click the link to review the publication )

Invest New Drugs, 2020, 4

PubMed: 32367199 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(6)

PubMed: 30875757 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30563080 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):965

PubMed: 30305055 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 10.1158/0008-5472.CAN-16-3424

PubMed: ( click the link to review the publication )

Genome Med, 2017, 9(1):40

PubMed: 28446242 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):52

PubMed: 28403890 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

FEBS J, 2017, 284(2):222-236

PubMed: 27860276 ( click the link to review the publication )

Antimicrob Agents Chemother, 2017, 61(3)

PubMed: 27993855 ( click the link to review the publication )

Electrophoresis, 2017, 10.1002/elps.201600447

PubMed: 28608427 ( click the link to review the publication )

J Exp Med, 2017, 214(6):1691-1710

PubMed: 28450382 ( click the link to review the publication )
Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

Blood, 2016, 6;128(14):1834-1844

PubMed: 27465916 ( click the link to review the publication )

Nat Commun, 2016, 7:11190

PubMed: 27048913 ( click the link to review the publication )

Autophagy, 2016, 2;12(6):999-1014

PubMed: 27124102 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2016, 8(21):13218-31

PubMed: 27160664 ( click the link to review the publication )

Antiviral Res, 2016, 126:69-80

PubMed: 26738783 ( click the link to review the publication )

Cancer Cell Int, 2016, 16:27

PubMed: 27042160 ( click the link to review the publication )

Int J Oncol, 2016, 49(3):953-60

PubMed: 27572939 ( click the link to review the publication )

Oncotarget, 2016, 7(3):3520-32

PubMed: 26657288 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Oncotarget, 2016, 7(35):56253-56265

PubMed: 27494845 ( click the link to review the publication )

Oncotarget, 2016, 8(36):60060-60079

PubMed: 28947954 ( click the link to review the publication )

Nat Chem Biol, 2015, 10.1038/nchembio.1986

PubMed: 26656090 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.05.008

PubMed: 25979228 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e2014

PubMed: 26658189 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: 25308513 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2015, 15:97

PubMed: 26464561 ( click the link to review the publication )

Int J Oncol, 2015, 46(4):1844-8

PubMed: 25647738 ( click the link to review the publication )

BMC Cancer, 2015, 15:919

PubMed: 26585594 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

Mol Cells, 2015, 38(3):279-84

PubMed: 25666350 ( click the link to review the publication )

Anticancer Drugs, 2015, 26(3):331-42

PubMed: 25521557 ( click the link to review the publication )
Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

J Pharm Pharmacol, 2015, 67(11):1575-84

PubMed: 26255619 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(5):755-67

PubMed: 25012986 ( click the link to review the publication )

Oral Oncol, 2014, 50(2):120-7

PubMed: 24216166 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 58(7):3689-96

PubMed: 24752266 ( click the link to review the publication )

Biochem Pharmacol, 2014, 92(1):55-61

PubMed: 25107702 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Exp Cell Res, 2014, 322(1):217-25

PubMed: 24355809 ( click the link to review the publication )

Life Sci, 2014, 10.1016/j.lfs.2014.07.006

PubMed: 25066930 ( click the link to review the publication )

Oncol Rep, 2014, 32(6):2789-94

PubMed: 25333301 ( click the link to review the publication )

J Cell Biochem, 2014, 115(9):1624-35

PubMed: 24788582 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

Genes Cancer, 2014, 5(11-12):445-59

PubMed: 25568669 ( click the link to review the publication )

Erasmus University Rotterdam, 2014, 978-94-6259-077-9

PubMed: http://repub.eur.nl/pub/50827/ ( click the link to review the publication )

Int J Cancer, 2013, 133(8):1813-24

PubMed: 23580240 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(4):448-59

PubMed: 23395885 ( click the link to review the publication )

J Immunol, 2013, 190(9):4621-6

PubMed: 23547112 ( click the link to review the publication )

Apoptosis, 2013, 18(10):1163-74

PubMed: 23887890 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 49(4):609-18

PubMed: 23668615 ( click the link to review the publication )

Exp Cell Res, 2013, 319(10):1443-50

PubMed: 23416067 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55982

PubMed: 23418490 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )
Cancer Res, 2012, 72(12):3069-79

PubMed: 22525702 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e299

PubMed: 22513873 ( click the link to review the publication )

Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

BMC Cancer, 2011, 11:24

PubMed: 21247487 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features

Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Targets

Bcl-2 ^[1]
(Cell-free assay)

0.22 μM(Ki)

In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. ^[1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. ^[2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KARPAS-45	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\3ZplpUUN3ME2wMlAxODB\|MUeg{txO	MUXTRW5ITVJ?
SK-MEL-30	M2XhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\oTWM2OD1yLkCwNFM2PSEQvF2=	NY[2cGFVW0GQR1XS
NALM-6	M1;Q[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PjNWlEPTB;MD6wNFA{PTZizszN	MnT2V2FPT0WU
KYSE-450	NH7XVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7VTWM2OD1yLkCwNFQ3QSEQvF2=	NV7vTohXW0GQR1XS
BHY	NF[3emlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV22PWlmUUN3ME2wMlAxODZyMTFOwG0>	NIfSeYVUSU6JRWK=
GR-ST	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHuTWM2OD1yLkCwNFY1QCEQvF2=	NHnOTIJUSU6JRWK=
786-0	NF3DN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nUWWlEPTB;MD6wNFA4PzZizszN	M3Phc3NCVkeHUh?=
C-33-A	M4HD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwMECwPFQ5KM7:TR?=	M4m3RXNCVkeHUh?=
BHT-101	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLuTWM2OD1yLkCwNVA3KM7:TR?=	NHrjTnpUSU6JRWK=
EB2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPieZJrUUN3ME2wMlAxOTF6IN88US=>	M{jib3NCVkeHUh?=
G-361	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojoTWM2OD1yLkCwNVI1KM7:TR?=	MoTXV2FPT0WU
KE-37	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTLWJNDUUN3ME2wMlAxOTJ6IN88US=>	MoPZV2FPT0WU
MHH-PREB-1	NVT3O5c1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmC1TWM2OD1yLkCwNVQh\|ryP	M4KxSXNCVkeHUh?=
MCF7	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHHTWM2OD1yLkCwNVU6KM7:TR?=	MnWzV2FPT0WU
LOUCY	MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrMTWM2OD1yLkCwNVc2KM7:TR?=	MUDTRW5ITVJ?
EW-7	NGTrcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwMECxO\|Uh\|ryP	MUfTRW5ITVJ?
KYSE-510	NF\PbIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jBNGlEPTB;MD6wNFI{OyEQvF2=	MVjTRW5ITVJ?
SK-MEL-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwMECyOlQh\|ryP	MYrTRW5ITVJ?
HAL-01	NFzOW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnLZ4Q6UUN3ME2wMlAxOjl5IN88US=>	M2jjWnNCVkeHUh?=
HCC2998	NHXoWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFv6[ZpKSzVyPUCuNFA{OzVizszN	NV3GbWFYW0GQR1XS
A375	M{[1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fRbmlEPTB;MD6wNFM2KM7:TR?=	MWPTRW5ITVJ?
MZ7-mel	NF\PU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvLTWM2OD1yLkCwN\|k6KM7:TR?=	NFnWfZhUSU6JRWK=
SH-4	NYj3dZUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LwRmlEPTB;MD6wNFQyPyEQvF2=	NGLnT3hUSU6JRWK=
HT-144	MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwMEC0N{DPxE1?	M2\K[nNCVkeHUh?=
KYSE-140	M1PuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMEC0N\|Uh\|ryP	NFzJXpZUSU6JRWK=
PSN1	NFzUbWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{iy[GlEPTB;MD6wNFQ3PyEQvF2=	M3rp[nNCVkeHUh?=
COLO-679	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\RdFJnUUN3ME2wMlAxPDl6IN88US=>	MoDnV2FPT0WU
SW620	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMEC1NVEh\|ryP	NGnMZYRUSU6JRWK=
HGC-27	MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\VZXBKSzVyPUCuNFA2OjRizszN	MVTTRW5ITVJ?
IGROV-1	Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHYeFRHUUN3ME2wMlAxPiEQvF2=	NYfRfpp6W0GQR1XS
IGR-1	MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3LfIhKSzVyPUCuNFA3ODFizszN	M3y2eHNCVkeHUh?=
EW-1	NVjtSGhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrHTWM2OD1yLkCwOlUyKM7:TR?=	MlnSV2FPT0WU
769-P	M3:5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH75[pJKSzVyPUCuNFA3PzhizszN	MY\TRW5ITVJ?
HN	NIHBdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF72XopKSzVyPUCuNFA3PzlizszN	MoDIV2FPT0WU
SIG-M5	NYHwOox5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEj5dlRKSzVyPUCuNFA4OSEQvF2=	Mn73V2FPT0WU
IST-MEL1	M3\6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fVZWlEPTB;MD6wNFgyQCEQvF2=	Mo\4V2FPT0WU
ST486	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTnTWM2OD1yLkCwPFI2KM7:TR?=	NVW4TG5yW0GQR1XS
ES7	NHjKVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PldmlEPTB;MD6wNFg1PiEQvF2=	MXnTRW5ITVJ?
GAK	MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLhVIlNUUN3ME2wMlAxQDR6IN88US=>	M2K3eHNCVkeHUh?=
BB30-HNC	MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7iPZN3UUN3ME2wMlAxQDV6IN88US=>	M{X4fHNCVkeHUh?=
IPC-298	NVS1T2dXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXafmpnUUN3ME2wMlAxQTJ5IN88US=>	M4TVNXNCVkeHUh?=
NKM-1	NGHZOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3RRppKSzVyPUCuNFA6PzJizszN	Ml:1V2FPT0WU
RKO	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjKR5ZKSzVyPUCuNFExPDRizszN	M2L4VHNCVkeHUh?=
ACN	NEPv[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{Did2lEPTB;MD6wNVE{OSEQvF2=	M{e3dHNCVkeHUh?=
SW1417	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMEGyNlUh\|ryP	M1zNbHNCVkeHUh?=
SR	NWOzdoZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTBwMEGyN\|Uh\|ryP	Mn\5V2FPT0WU
SNG-M	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMEGzNVch\|ryP	M4CxWXNCVkeHUh?=
CAL-12T	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\ROGlEPTB;MD6wNVM1PiEQvF2=	M2fTUXNCVkeHUh?=
HSC-3	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\DWG05UUN3ME2wMlAyOzV3IN88US=>	Moe5V2FPT0WU
DOHH-2	MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\5ZollUUN3ME2wMlAyPDF{IN88US=>	MmryV2FPT0WU
NB69	NH;STXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nKTmlEPTB;MD6wNVU3PSEQvF2=	NFXkNGNUSU6JRWK=
LC-2-ad	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvmOmpKSzVyPUCuNFE2QDFizszN	MWPTRW5ITVJ?
RVH-421	NHr1VndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorGTWM2OD1yLkCxOlc1KM7:TR?=	MVPTRW5ITVJ?
TGW	NUniOJhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTBwMEG3N\|kh\|ryP	NUjBOWlqW0GQR1XS
HCC1569	M3HVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4r4ZmlEPTB;MD6wNVc6PyEQvF2=	M37KU3NCVkeHUh?=
CAL-85-1	NFWweVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMEG4N\|Ih\|ryP	NXPtWJF3W0GQR1XS
RPMI-8402	Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVi4T5ROUUN3ME2wMlAyQDV6IN88US=>	MY\TRW5ITVJ?
THP-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DyNmlEPTB;MD6wNVk6QCEQvF2=	MonvV2FPT0WU
ONS-76	NWq3O4x2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMEKwN\|Yh\|ryP	Ml7YV2FPT0WU
A2780	M4rPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMEKwO\|kh\|ryP	NF\ySJpUSU6JRWK=
RPMI-2650	Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vQZWlEPTB;MD6wNlI6PiEQvF2=	MUPTRW5ITVJ?
MEL-HO	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nBRWlEPTB;MD6wNlM1QCEQvF2=	MXXTRW5ITVJ?
MC-CAR	NVvtWVMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwMEKzOVYh\|ryP	M2PBb3NCVkeHUh?=
HSC-2	NIPtRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkX0TWM2OD1yLkCyOFY3KM7:TR?=	NH7mRmlUSU6JRWK=
MEL-JUSO	MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHWWVFKSzVyPUCuNFI1PzNizszN	MYjTRW5ITVJ?
CAL-62	NU\DWGRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljyTWM2OD1yLkCyOlAzKM7:TR?=	NU\DfJZJW0GQR1XS
DMS-273	NWTnZ4RST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jZNWlEPTB;MD6wNlg1PyEQvF2=	NV3LTHN2W0GQR1XS
S-117	NVzje2FbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFr6XlVKSzVyPUCuNFI6ODZizszN	MnzGV2FPT0WU
SUP-T1	MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHK5Z2tKSzVyPUCuNFI6PDlizszN	NIX3fYxUSU6JRWK=
MZ2-MEL	M1S3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;DeGlEPTB;MD6wNlk2QSEQvF2=	M3zDTnNCVkeHUh?=
KYSE-270	M3XQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2Ph[WlEPTB;MD6wNlk4PiEQvF2=	NWn2dndMW0GQR1XS
CMK	MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDoNW1KSzVyPUCuNFMxOjNizszN	MnS2V2FPT0WU
8505C	Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwMEOwOEDPxE1?	MoL1V2FPT0WU
NUGC-3	NG\CdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LofmlEPTB;MD6wN\|A1QCEQvF2=	M3HZWnNCVkeHUh?=
A101D	MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX72PJd1UUN3ME2wMlA{ODV3IN88US=>	M37UOnNCVkeHUh?=
G-401	NEjzZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXjSVhKSzVyPUCuNFMxQTNizszN	NFz2N4JUSU6JRWK=
OVCAR-8	NICwZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDHUGxKSzVyPUCuNFMyODdizszN	NYDhUphQW0GQR1XS
IMR-5	NH72fG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIr3NoxKSzVyPUCuNFMzPDRizszN	MkfCV2FPT0WU
DoTc2-4510	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPNTWM2OD1yLkCzN\|k{KM7:TR?=	NVL3bpI1W0GQR1XS
HOS	NUS3eIo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TVU2lEPTB;MD6wN\|Q4OyEQvF2=	M1LiTXNCVkeHUh?=
HEC-1	Mn3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGf5[YtKSzVyPUCuNFM3QCEQvF2=	MmrlV2FPT0WU
SW756	M2G0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTQTWM2OD1yLkCzPFIyKM7:TR?=	MYnTRW5ITVJ?
NCI-H64	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwMEO4OFIh\|ryP	M2[y[nNCVkeHUh?=
EW-16	MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\XTWM2OD1yLkCzPVA6KM7:TR?=	NEiyS5NUSU6JRWK=
CAL-51	NUGybXRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwMESwNFUh\|ryP	M3HxVHNCVkeHUh?=
KYSE-150	MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\6UZJKSzVyPUCuNFQxOTFizszN	M4ixSXNCVkeHUh?=
SW1710	M3LzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF:yd3lKSzVyPUCuNFQxOThizszN	NFjnOGRUSU6JRWK=
HuP-T4	Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\VNmlEPTB;MD6wOFEyQCEQvF2=	NWewb2JWW0GQR1XS
LB373-MEL-D	NYjUZYw5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfOZm9KSzVyPUCuNFQzOzJizszN	MYPTRW5ITVJ?
EW-13	NULQUWx2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMES0NFYh\|ryP	MlvxV2FPT0WU
HT-29	M3nQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zDV2lEPTB;MD6wOFQ6KM7:TR?=	M4SxPHNCVkeHUh?=
SCC-25	NX7yVpFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIj4fZRKSzVyPUCuNFQ1QTRizszN	MXjTRW5ITVJ?
REH	M3zxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXZUoRqUUN3ME2wMlA1PjN3IN88US=>	MX7TRW5ITVJ?
L-363	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXX3[XFZUUN3ME2wMlA1Pjd7IN88US=>	NEKzV5BUSU6JRWK=
NCI-H1770	NWfJNJNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwMES2PVch\|ryP	NUHZUIRuW0GQR1XS
CHL-1	Mn;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGO2eVZKSzVyPUCuNFQ5PTdizszN	NFqzbotUSU6JRWK=
ES1	NFjFe5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlWxTWM2OD1yLkC0PFg2KM7:TR?=	M3nWXnNCVkeHUh?=
SCC-15	NEnCXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUe2WI9RUUN3ME2wMlA1QTB{IN88US=>	M2PodnNCVkeHUh?=
MRK-nu-1	NX\tXY06T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjPRoNKSzVyPUCuNFQ6OzZizszN	MkO5V2FPT0WU
PF-382	NHH0cGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwMES5N\|kh\|ryP	MoPPV2FPT0WU
COLO-680N	M3W2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\vbZJKUUN3ME2wMlA2ODR5IN88US=>	MomzV2FPT0WU
LK-2	NITPU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwMEWwOlMh\|ryP	NFjQRY1USU6JRWK=
NCI-H2342	M1P5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LI[WlEPTB;MD6wOVEyPyEQvF2=	NGrJcpZUSU6JRWK=
HMV-II	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWX5d5FnUUN3ME2wMlA2OjN7IN88US=>	MXvTRW5ITVJ?
PC-14	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHxTWM2OD1yLkC1NlUzKM7:TR?=	MVzTRW5ITVJ?
COLO-320-HSR	NIH1N3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIe4blRKSzVyPUCuNFUzQDlizszN	NHXHUIVUSU6JRWK=
697	M2LUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFqyUlZKSzVyPUCuNFU{OjNizszN	Mni5V2FPT0WU
NEC8	Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7nTWM2OD1yLkC1OVkh\|ryP	NUPuPJVGW0GQR1XS
LCLC-97TM1	NHjYbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwMEW1PVQh\|ryP	M{TKUHNCVkeHUh?=
Daoy	NYWybW56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHDTWM2OD1yLkC1OlE3KM7:TR?=	Ml[2V2FPT0WU
ETK-1	M3rRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfBTWM2OD1yLkC1OlczKM7:TR?=	MkDzV2FPT0WU
A388	M3vRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHHZWdnUUN3ME2wMlA2Pjl3IN88US=>	MX\TRW5ITVJ?
COLO-205	NX;iXGE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnQTWM2OD1yLkC1O\|E3KM7:TR?=	NXPYNIg1W0GQR1XS
SK-PN-DW	NUG4bWlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfhWJZIUUN3ME2wMlA2PzJ7IN88US=>	MoPoV2FPT0WU
SF268	MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwMEW3OVYh\|ryP	NVXUTFREW0GQR1XS
OCI-AML2	NV63S4l5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwMEW3O\|ch\|ryP	M4r3SHNCVkeHUh?=
GAMG	M1KwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TkVmlEPTB;MD6wOVgh\|ryP	NVfuOpB2W0GQR1XS
BCPAP	M{m2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwMEW4PVIh\|ryP	MVzTRW5ITVJ?
BC-1	MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwME[wNlIh\|ryP	MkThV2FPT0WU
IA-LM	NVu1ZnNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEewZ4ZKSzVyPUCuNFYxPTNizszN	NXu0TWcxW0GQR1XS
NCI-H1299	NHrKe3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXmTWM2OD1yLkC2NVMh\|ryP	NVq1eHBzW0GQR1XS
COR-L23	NGr2VnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXNTHlTUUN3ME2wMlA3OTN2IN88US=>	M2rMfHNCVkeHUh?=
KYSE-180	NH7iXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrETm1KSzVyPUCuNFYyPDJizszN	NUS2ZZMyW0GQR1XS
LOXIMVI	M1\UWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nmTmlEPTB;MD6wOlE5QCEQvF2=	MoXYV2FPT0WU
BL-41	M1\RUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHVblVrUUN3ME2wMlA3OjF7IN88US=>	NUTYUlk{W0GQR1XS
BL-70	M{TlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXkTWM2OD1yLkC2N\|AzKM7:TR?=	NGq5XJhUSU6JRWK=
NOS-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LxZWlEPTB;MD6wOlQyOSEQvF2=	M4jJSHNCVkeHUh?=
NB13	M2j6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVKzOlBlUUN3ME2wMlA3PDJzIN88US=>	MnH3V2FPT0WU
CAL-27	M1fIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TZU2lEPTB;MD6wOlQ3PCEQvF2=	MorqV2FPT0WU
CA46	M{jjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3ITWM2OD1yLkC2OVM4KM7:TR?=	M1jlXXNCVkeHUh?=
SW962	NX73TGtkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\2OWlEPTB;MD6wOlU3QSEQvF2=	NUf5NmxXW0GQR1XS
NCI-H226	NVvkfmxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGr0N5dKSzVyPUCuNFY3OzJizszN	NWq1[3pDW0GQR1XS
KYSE-70	NXe2VJR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwME[5OFUh\|ryP	NED1UIZUSU6JRWK=
Daudi	NGftcWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF73SpBKSzVyPUCuNFcxQDFizszN	MXLTRW5ITVJ?
SW626	MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mon2TWM2OD1yLkC3NlA1KM7:TR?=	NWi3U\|B2W0GQR1XS
ESS-1	Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELHXpNKSzVyPUCuNFczPDZizszN	NWXqT5FtW0GQR1XS
YT	NHnUdppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYexXGlHUUN3ME2wMlA4OzR3IN88US=>	NEnrbZRUSU6JRWK=
P12-ICHIKAWA	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDETWM2OD1yLkC3N\|Q6KM7:TR?=	M1XFUnNCVkeHUh?=
BxPC-3	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwMEe0OVgh\|ryP	MlflV2FPT0WU
CTV-1	NILmeWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonCTWM2OD1yLkC3OVE4KM7:TR?=	MVTTRW5ITVJ?
MLMA	NGraT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwMEe1N\|Qh\|ryP	NEPkNWNUSU6JRWK=
WSU-NHL	NFjvSWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XLTmlEPTB;MD6wO\|U2PCEQvF2=	MWDTRW5ITVJ?
CTB-1	NFzFdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTBwMEe1PFgh\|ryP	NFLpXWZUSU6JRWK=
MMAC-SF	NULqOIN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\YZmlEPTB;MD6wO\|Y3QCEQvF2=	NV7jT2xsW0GQR1XS
8-MG-BA	MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HMUmlEPTB;MD6wO\|gxOSEQvF2=	MoLxV2FPT0WU
NCI-H358	MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoGxTWM2OD1yLkC3PFc6KM7:TR?=	MUnTRW5ITVJ?
BFTC-905	M4TBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXnTWM2OD1yLkC3PVA6KM7:TR?=	Mm\pV2FPT0WU
NCI-H727	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3UOmpKSzVyPUCuNFgxPTNizszN	NELUOIpUSU6JRWK=
CHP-212	NV;Pe2JHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;EPJdKSzVyPUCuNFgxQTVizszN	NXGzU\|lSW0GQR1XS
HOP-62	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMEiyOFUh\|ryP	M2fCOnNCVkeHUh?=
CESS	NEn1[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37Q[2lEPTB;MD6wPFI3QSEQvF2=	MoG4V2FPT0WU
HuCCT1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7jd4JsUUN3ME2wMlA5OzN\|IN88US=>	NYTkeYVXW0GQR1XS
DEL	MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml22TWM2OD1yLkC4N\|Q4KM7:TR?=	NHXXdYpUSU6JRWK=
5637	M2O5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfYVIdGUUN3ME2wMlA5OzZ5IN88US=>	MlXKV2FPT0WU
RS4-11	NGOzbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDiTWM2OD1yLkC4OFk4KM7:TR?=	MkXvV2FPT0WU
KURAMOCHI	MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLYcFk5UUN3ME2wMlA5PTB7IN88US=>	NYLFco9YW0GQR1XS
A427	M4fEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\L[nFKSzVyPUCuNFg2OTJizszN	NXf3WYp{W0GQR1XS
A3-KAW	NUPQZ\|ZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDoWWhKSzVyPUCuNFg2PjZizszN	NUKyR5JEW0GQR1XS
LS-123	MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXZOVNRUUN3ME2wMlA5PzF7IN88US=>	MlTTV2FPT0WU
LoVo	M1PUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnX4TWM2OD1yLkC4O\|Ih\|ryP	NWSxbFJlW0GQR1XS
PA-1	NXGzSWlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPMUo5KSzVyPUCuNFg4PjlizszN	MljhV2FPT0WU
CP50-MEL-B	NFzOcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH:2R\|BKSzVyPUCuNFg4QTNizszN	NFLxN3JUSU6JRWK=
A431	M{fjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnv2TWM2OD1yLkC4PFAyKM7:TR?=	NWf6VHRJW0GQR1XS
HCT-116	NH;KdVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUm5e45VUUN3ME2wMlA5QDB{IN88US=>	NWLqcHJsW0GQR1XS
A4-Fuk	NGLKelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnVN3JnUUN3ME2wMlA5QTR5IN88US=>	M4fQNHNCVkeHUh?=
RPMI-6666	NXvkeJZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXZTWM2OD1yLkC4PVY4KM7:TR?=	MVfTRW5ITVJ?
Calu-6	NIDTV\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIexb4tKSzVyPUCuNFkxOjlizszN	NGK1XGNUSU6JRWK=
KMOE-2	NF3YW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzWTWM2OD1yLkC5NFM6KM7:TR?=	MkD6V2FPT0WU
A704	MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3z3VWlEPTB;MD6wPVE2KM7:TR?=	MULTRW5ITVJ?
HO-1-N-1	MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMEmyOFkh\|ryP	Mk\CV2FPT0WU
NCI-H2122	MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwMEmzO\|gh\|ryP	NV;JS45GW0GQR1XS
U-698-M	MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHGTWM2OD1yLkC5OFA6KM7:TR?=	M1K0R3NCVkeHUh?=
IST-SL2	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPLTZpKSzVyPUCuNFk1PjhizszN	NH;TXpdUSU6JRWK=
TE-10	NGXnenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTzTWM2OD1yLkC5OVg1KM7:TR?=	MXfTRW5ITVJ?
PANC-03-27	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\zR28zUUN3ME2wMlA6PjdzIN88US=>	NHnSXlhUSU6JRWK=
KYSE-410	M1vtfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33VNWlEPTB;MD6wPVc6PyEQvF2=	M33xTXNCVkeHUh?=
TE-8	NEjwc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInZemVKSzVyPUCuNFk5QDVizszN	MmXqV2FPT0WU
MN-60	MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17kemlEPTB;MD6wPVg6PyEQvF2=	MlS0V2FPT0WU
NCI-H460	NXS0e29wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGP6TnhKSzVyPUCuNVAxQSEQvF2=	MkjLV2FPT0WU
LB771-HNC	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2S3TWlEPTB;MD6xNFI2PSEQvF2=	NFH4UWVUSU6JRWK=
ES4	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXGXIFPUUN3ME2wMlExOjZ2IN88US=>	NVfYSXF2W0GQR1XS
HUTU-80	Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDRblV3UUN3ME2wMlExOzZ3IN88US=>	MlfkV2FPT0WU
647-V	NVzybotNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMUC0NFgh\|ryP	Mn7HV2FPT0WU
HTC-C3	M2i2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMUC0N\|Ih\|ryP	MlexV2FPT0WU
NTERA-S-cl-D1	NInITmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMUC0OFgh\|ryP	MVfTRW5ITVJ?
A2058	NIPCb\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn:0TWM2OD1yLkGwOlU2KM7:TR?=	NIf6boZUSU6JRWK=
MZ1-PC	MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mly2TWM2OD1yLkGwPFMh\|ryP	NFrMXnpUSU6JRWK=
J82	NHvsT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XOTmlEPTB;MD6xNFg5PCEQvF2=	NIDDN5dUSU6JRWK=
ARH-77	M4X2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\WXGlEPTB;MD6xNUDPxE1?	NXTwPYJFW0GQR1XS
Ca9-22	M2ruNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV2wPJluUUN3ME2wMlEyOTJ6IN88US=>	MXTTRW5ITVJ?
NCI-H1648	M2PXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mly3TWM2OD1yLkGxNlg3KM7:TR?=	NV72flRkW0GQR1XS
MC116	M17JU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\PVWlEPTB;MD6xNVM{PyEQvF2=	M2HTN3NCVkeHUh?=
EoL-1-cell	MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInxWZlKSzVyPUCuNVE1PjdizszN	NHjLe21USU6JRWK=
PANC-10-05	NF6wVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrwTWM2OD1yLkGxOFkyKM7:TR?=	NWK1OmpHW0GQR1XS
SF539	M4mwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HBVGlEPTB;MD6xNVYyPiEQvF2=	NFjTWnVUSU6JRWK=
ES8	MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LJZ2lEPTB;MD6xNVY{OyEQvF2=	M1vCcHNCVkeHUh?=
NCI-H810	Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13Ub2lEPTB;MD6xNVY3PCEQvF2=	M332R3NCVkeHUh?=
J-RT3-T3-5	NF[zN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1voOmlEPTB;MD6xNVc2KM7:TR?=	NIjpZVBUSU6JRWK=
NY	NHKyVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHvc\|RXUUN3ME2wMlEyQDF5IN88US=>	MmnmV2FPT0WU
NCI-SNU-1	Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrBd3Q5UUN3ME2wMlEzOTR6IN88US=>	NXPY[2RIW0GQR1XS
EFM-19	NYDHV5h7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUGwO\|VxUUN3ME2wMlEzOzd2IN88US=>	NY\Ge\|dHW0GQR1XS
HCC1806	Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV23SWw3UUN3ME2wMlEzOzh\|IN88US=>	MVPTRW5ITVJ?
HCE-T	NGPkUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHjcGlKSzVyPUCuNVI2OzFizszN	MXnTRW5ITVJ?
HT-1376	Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LnTWlEPTB;MD6xNlY3QCEQvF2=	MXTTRW5ITVJ?
BE-13	NV\PbYxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn[yTWM2OD1yLkGyPFY3KM7:TR?=	M{T5[3NCVkeHUh?=
NCI-H520	Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nTdmlEPTB;MD6xNlg3PyEQvF2=	NISxTFlUSU6JRWK=
SK-MES-1	M{Tad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULORoFKUUN3ME2wMlEzQTF\|IN88US=>	NHr6WXNUSU6JRWK=
SNU-423	M2jVXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml35TWM2OD1yLkGyPVE1KM7:TR?=	MknQV2FPT0WU
Ramos-2G6-4C10	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfSVpNKSzVyPUCuNVI6OTZizszN	M33N[HNCVkeHUh?=
EW-18	MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;XeG1KSzVyPUCuNVMxOjZizszN	M3n2RnNCVkeHUh?=
NCI-H2087	M2j5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMUOwNlch\|ryP	M4jKSXNCVkeHUh?=
COLO-792	Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjSb29pUUN3ME2wMlE{OTZ3IN88US=>	NVfqWYFbW0GQR1XS
QIMR-WIL	NGr3Z3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljwTWM2OD1yLkGzNlI{KM7:TR?=	NXuwN25kW0GQR1XS
ACHN	NF3uR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnwVpNuUUN3ME2wMlE{OjR5IN88US=>	M4OwOHNCVkeHUh?=
RPMI-8866	NIK1TpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDjTWM2OD1yLkGzNlYyKM7:TR?=	M2jVO3NCVkeHUh?=
SK-LU-1	NV\SbmJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTUUVI1UUN3ME2wMlE{PDR7IN88US=>	M3PHeXNCVkeHUh?=
SK-UT-1	MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMUO2Nlgh\|ryP	M3PuPXNCVkeHUh?=
MFE-296	MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknHTWM2OD1yLkGzPFY1KM7:TR?=	M4LlS3NCVkeHUh?=
RD	M37vTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMUO5PVch\|ryP	MnfSV2FPT0WU
LS-411N	NVnDOFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlq3TWM2OD1yLkG0Nlk2KM7:TR?=	NY\Ufo4zW0GQR1XS
NCI-H747	Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwMUSzJO69VQ>?	NVvN[GZmW0GQR1XS
ES6	NWjKZ2g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHKWJlnUUN3ME2wMlE1OzZizszN	NHz4U4tUSU6JRWK=
TE-1	MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jQTWlEPTB;MD6xOFQxPyEQvF2=	NHfxbVVUSU6JRWK=
SJSA-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnCUm1TUUN3ME2wMlE1PzB5IN88US=>	M{\V[HNCVkeHUh?=
NCI-H1355	NU\TbXQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMUWyPVMh\|ryP	NUfGOpZvW0GQR1XS
HEL	MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwMUW0OFch\|ryP	Mn3YV2FPT0WU
639-V	NUTWeHhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;PTWM2OD1yLkG1OVk3KM7:TR?=	NHjBSmxUSU6JRWK=
AN3-CA	M1;QUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTwdGV6UUN3ME2wMlE2PjN7IN88US=>	NHXvb4xUSU6JRWK=
SK-MEL-2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXXNpNKSzVyPUCuNVU3PjhizszN	NUizdnNuW0GQR1XS
SW872	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELPeGpKSzVyPUCuNVYxPDJizszN	NYexdmN[W0GQR1XS
DU-4475	M3frdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXO2cmJbUUN3ME2wMlE3OTZ{IN88US=>	NH2w[odUSU6JRWK=
YKG-1	M33GUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXVWXpKSzVyPUCuNVYzPzNizszN	MYTTRW5ITVJ?
GT3TKB	M1;qcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjDWotKSzVyPUCuNVYzQDNizszN	NIexbWFUSU6JRWK=
GB-1	M4jzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMU[0NlQh\|ryP	NW\GSYU1W0GQR1XS
KARPAS-422	NIP5[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PlNmlEPTB;MD6xOlU4PCEQvF2=	NXzNOXVnW0GQR1XS
ATN-1	Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3STWM2OD1yLkG2OlU3KM7:TR?=	NUDkNFRPW0GQR1XS
HLE	MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTPdmE4UUN3ME2wMlE3QDd5IN88US=>	MkLJV2FPT0WU
D-542MG	NYnR[2tLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPHTWM2OD1yLkG2PVg3KM7:TR?=	M3zDNnNCVkeHUh?=
EB-3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXzTWM2OD1yLkG3N\|Eh\|ryP	M4PtXHNCVkeHUh?=
HCC1143	M3;4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7JTIxJUUN3ME2wMlE4Ozl4IN88US=>	MXfTRW5ITVJ?
DJM-1	M33ieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHoc3FKSzVyPUCuNVc1PTFizszN	MnjVV2FPT0WU
BT-474	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnmR2pKSzVyPUCuNVc1QDlizszN	MUfTRW5ITVJ?
BB65-RCC	NFPCXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLQTWM2OD1yLkG3OVQ2KM7:TR?=	MnX1V2FPT0WU
NCI-H292	M{S5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMUe2NFEh\|ryP	NH6wSZJUSU6JRWK=
MKN28	MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Dne2lEPTB;MD6xO\|Y2OyEQvF2=	NH\ydWRUSU6JRWK=
TK10	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fPZ2lEPTB;MD6xO\|cxOiEQvF2=	MnXFV2FPT0WU
TYK-nu	NGnLTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY[zUHN5UUN3ME2wMlE4QTR7IN88US=>	NVTYZ3l6W0GQR1XS
8305C	NYj3TVNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4r2bmlEPTB;MD6xO\|k4OSEQvF2=	NU\WbJN6W0GQR1XS
MV-4-11	Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwMUe5O\|ch\|ryP	MYrTRW5ITVJ?
NCI-H522	NG\ZXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rSRmlEPTB;MD6xPFA6PCEQvF2=	NVPlZmt6W0GQR1XS
Hs-578-T	NFXZSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPjNplKSzVyPUCuNVgzQTJizszN	M17aVXNCVkeHUh?=
LCLC-103H	NFfrPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHOyTHpKSzVyPUCuNVg2OjdizszN	M2j4ZnNCVkeHUh?=
MHH-ES-1	NVnLfWFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vLTmlEPTB;MD6xPFYzQSEQvF2=	MXLTRW5ITVJ?
NCI-H441	MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwMUmxOFgh\|ryP	M2PtcHNCVkeHUh?=
AM-38	M13ONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPUc4NKSzVyPUCuNVkzOjVizszN	MkK3V2FPT0WU
SW1783	NWrDdlVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjodm9KSzVyPUCuNVk{ODVizszN	NFruenRUSU6JRWK=
SK-HEP-1	NVjhc4U6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMUm2N\|ch\|ryP	MWLTRW5ITVJ?
OAW-28	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMkCxO\|gh\|ryP	MmnuV2FPT0WU
TE-15	Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGOwc2VKSzVyPUCuNlAzPTJizszN	NWDXZY1nW0GQR1XS
HCE-4	Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMkCyPFQh\|ryP	NHX5SWtUSU6JRWK=
JiyoyeP-2003	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXsVINKSzVyPUCuNlA{OzZizszN	M{TRUXNCVkeHUh?=
OVCAR-4	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTBwMkC2Nlgh\|ryP	M3r2NHNCVkeHUh?=
SNU-449	M3f3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PvNGlEPTB;MD6yNFc6PyEQvF2=	M{nWOXNCVkeHUh?=
SBC-5	NVrJT\|V4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3MTWM2OD1yLkKxNlE2KM7:TR?=	NUS2b4p[W0GQR1XS
T84	NGXMNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDiSmpKSzVyPUCuNlEzPDhizszN	NEG3VoFUSU6JRWK=
LP-1	NHy0PZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnVfZRKSzVyPUCuNlE{ODJizszN	M2XhdXNCVkeHUh?=
MG-63	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPC[3NKSzVyPUCuNlE{QDJizszN	MoXwV2FPT0WU
OAW-42	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwMkG0O\|gh\|ryP	Mn;2V2FPT0WU
L-540	Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo[xTWM2OD1yLkKxOVk5KM7:TR?=	NWXScHVGW0GQR1XS
RH-1	M{nBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnwPHpMUUN3ME2wMlIzOjR{IN88US=>	NULZWpI2W0GQR1XS
HCT-15	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLyTWM2OD1yLkKyOFg1KM7:TR?=	MUHTRW5ITVJ?
OCUB-M	M4rnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMkK0PFgh\|ryP	NFXDNWhUSU6JRWK=
GP5d	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwMkK1Nlgh\|ryP	MlOxV2FPT0WU
NCI-H2030	M1zlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwMkK3N\|Qh\|ryP	MV3TRW5ITVJ?
ML-2	NIXUPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHX2OYhKSzVyPUCuNlI5QDlizszN	MlnJV2FPT0WU
CAL-39	Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MortTWM2OD1yLkKyPVM3KM7:TR?=	NUW4bmFQW0GQR1XS
MIA-PaCa-2	M1;2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorYTWM2OD1yLkKzNlg4KM7:TR?=	M1j3[XNCVkeHUh?=
TE-9	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3f1ZmlEPTB;MD6yN\|MzKM7:TR?=	M{TZVnNCVkeHUh?=
LB2518-MEL	NVqzZoI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWexSoRwUUN3ME2wMlI{Ozd{IN88US=>	M4TwRXNCVkeHUh?=
DB	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwMkO0N\|gh\|ryP	NXnvTFFrW0GQR1XS
NCI-H596	NHPOWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHv1Um1KSzVyPUCuNlM2PzFizszN	NH\xTZhUSU6JRWK=
SW1990	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjrTWc2UUN3ME2wMlI{QTR4IN88US=>	Ml7OV2FPT0WU
P30-OHK	Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlf0TWM2OD1yLkK0NFUh\|ryP	M2D0Z3NCVkeHUh?=
ALL-PO	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXyzdnlvUUN3ME2wMlI1OTZ7IN88US=>	MXTTRW5ITVJ?
Saos-2	NX7xbVdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjYTWM2OD1yLkK0OVcyKM7:TR?=	MYDTRW5ITVJ?
MFH-ino	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDQfmV3UUN3ME2wMlI1Pjl{IN88US=>	MkHrV2FPT0WU
OE33	NVzueGc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHK3bnNKSzVyPUCuNlUyOSEQvF2=	MVjTRW5ITVJ?
Calu-3	NHThXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DiRmlEPTB;MD6yOVI6PyEQvF2=	MmDmV2FPT0WU
HT	M17SWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwMkW2NlEh\|ryP	MknEV2FPT0WU
LXF-289	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmf0TWM2OD1yLkK1PVg1KM7:TR?=	MV7TRW5ITVJ?
KGN	MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMk[wPFkh\|ryP	NEfodVVUSU6JRWK=
NCI-H1417	NWnobWQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XQR2lEPTB;MD6yOlUzPCEQvF2=	MkfJV2FPT0WU
SF126	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwMkezNFIh\|ryP	MWPTRW5ITVJ?
SAS	NFrsdWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMkezNFgh\|ryP	M1f2OXNCVkeHUh?=
22RV1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTBwMkezO\|gh\|ryP	M2HsdHNCVkeHUh?=
GI-1	NE[1cYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwMke0PFch\|ryP	NHi3V2xUSU6JRWK=
ES3	NYL5W5N6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHaUGl[UUN3ME2wMlI4PzZ\|IN88US=>	NE\adolUSU6JRWK=
NB1	Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjWTWM2OD1yLkK3PFc3KM7:TR?=	Mn\lV2FPT0WU
NCI-H650	NVWwfpQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfMTWM2OD1yLkK4N\|AzKM7:TR?=	MonJV2FPT0WU
IST-MES1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PJTGlEPTB;MD6yPFU2PCEQvF2=	M4O1RXNCVkeHUh?=
UM-UC-3	NHz1SWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13CSmlEPTB;MD6yPVE1KM7:TR?=	NFfqdVVUSU6JRWK=
CAL-120	Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\hW3FuUUN3ME2wMlI6PjNzIN88US=>	MnPHV2FPT0WU
UACC-62	M3\pVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnFXJE4UUN3ME2wMlMxOjRzIN88US=>	NFnlT3dUSU6JRWK=
TE-11	NELrSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnnbmNzUUN3ME2wMlMxOjR7IN88US=>	NGnDSWFUSU6JRWK=
MKN1	M2fBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwM{CzOkDPxE1?	NED6NHRUSU6JRWK=
KS-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTBwM{C1NlYh\|ryP	MkHhV2FPT0WU
GCIY	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwM{GwNFIh\|ryP	NH7hVJRUSU6JRWK=
OVCAR-5	NH3y[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn2yTWM2OD1yLkOxNVA3KM7:TR?=	MYnTRW5ITVJ?
U-266	NHrlPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jKfGlEPTB;MD6zNVE1PyEQvF2=	MoPoV2FPT0WU
Calu-1	Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmi4TWM2OD1yLkOxNlg6KM7:TR?=	M4C1TnNCVkeHUh?=
SK-LMS-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXuTWM2OD1yLkOxOFI6KM7:TR?=	MWDTRW5ITVJ?
COLO-741	NV7UUFh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVi1SGlxUUN3ME2wMlMyPjF2IN88US=>	MXXTRW5ITVJ?
RPMI-8226	NYHEfpc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHL4O3ZKSzVyPUCuN\|E3PDFizszN	MnfmV2FPT0WU
KM12	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PrOGlEPTB;MD6zNVg{KM7:TR?=	NYPtUmF3W0GQR1XS
NMC-G1	NHLJ[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLzTWM2OD1yLkOxPFYh\|ryP	NWjlb2tJW0GQR1XS
SJRH30	NYjwS3NnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLwd3pPUUN3ME2wMlMzODV{IN88US=>	M4\CWHNCVkeHUh?=
COR-L105	NYG4XXllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwM{KyNVgh\|ryP	NXXqfI5IW0GQR1XS
IM-9	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPDNGdKSzVyPUCuN\|MxOjFizszN	M4KxWHNCVkeHUh?=
TE-12	NF\LU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mki5TWM2OD1yLkOzN\|E4KM7:TR?=	NYXtUHZvW0GQR1XS
KG-1	NV7KPGtxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XPRmlEPTB;MD6zN\|Q{OiEQvF2=	MVHTRW5ITVJ?
U251	MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jSUWlEPTB;MD6zN\|Q2PiEQvF2=	MWnTRW5ITVJ?
EFO-27	NVTSW2NMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTtVWd1UUN3ME2wMlM{QTVzIN88US=>	NH7qSJhUSU6JRWK=
EW-24	NHvPNm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XsUmlEPTB;MD6zN\|k5PCEQvF2=	MnXDV2FPT0WU
SF295	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTYZY5KSzVyPUCuN\|M6QTlizszN	NV[xPYNqW0GQR1XS
MC-IXC	NH;Id\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nNVWlEPTB;MD6zOFUh\|ryP	M3qw[HNCVkeHUh?=
NCI-H2405	NXLxNZVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXK5WlJKUUN3ME2wMlM1PzN{IN88US=>	MYXTRW5ITVJ?
NCI-H2009	M17rNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjFTWM2OD1yLkO0O\|M6KM7:TR?=	MnLZV2FPT0WU
LB1047-RCC	M4jTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vUdWlEPTB;MD6zOVgyPSEQvF2=	MUPTRW5ITVJ?
KNS-81-FD	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwM{[2Olch\|ryP	MkD0V2FPT0WU
HOP-92	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\kTWM2OD1yLkO2PFMh\|ryP	NGH3Rm1USU6JRWK=
L-428	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\BTWM2OD1yLkO3NFE3KM7:TR?=	M2rLSXNCVkeHUh?=
C3A	NHPmWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwM{ezO\|kh\|ryP	M17L[HNCVkeHUh?=
NCI-H1792	MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XNZWlEPTB;MD6zO\|Y2PSEQvF2=	NWHqcGhKW0GQR1XS
HuH-7	NHjhO\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwM{e5NUDPxE1?	MmHIV2FPT0WU
AGS	NWrM[2RsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\MV2lEPTB;MD6zPFY{QCEQvF2=	MUHTRW5ITVJ?
HT-1197	NXu0[mJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYn5TZVMUUN3ME2wMlM6PDZizszN	NFiz[YlUSU6JRWK=
CGTH-W-1	NUW1S41IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwM{m5NVMh\|ryP	MkXpV2FPT0WU
KNS-42	M160Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwNECwOFUh\|ryP	NYWyN2NwW0GQR1XS
HuO-3N1	NVf1ZVZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwNECwOVUh\|ryP	NI\UPYhUSU6JRWK=
VMRC-RCZ	NV75WnhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzXTWM2OD1yLkSwN\|A{KM7:TR?=	MlPUV2FPT0WU
SW954	MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwNECzN\|Uh\|ryP	NUHhPJdlW0GQR1XS
MES-SA	M3Kyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn31TWM2OD1yLkSwOVA2KM7:TR?=	M4TnRXNCVkeHUh?=
Ca-Ski	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUWzUZN6UUN3ME2wMlQxPTJ2IN88US=>	MVPTRW5ITVJ?
SW13	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\oTGlEPTB;MD60NFYzPiEQvF2=	NXTIdlRzW0GQR1XS
NCI-H1437	M4nQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnBTWtKSzVyPUCuOFA5ODVizszN	MV3TRW5ITVJ?
U-118-MG	NVrKeJpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLKdZoyUUN3ME2wMlQxQTB2IN88US=>	NX\RVVRMW0GQR1XS
NCI-H1734	NXvVUWNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHHc4hLUUN3ME2wMlQzODF\|IN88US=>	MVvTRW5ITVJ?
HDLM-2	M3jscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwNEKwN\|Mh\|ryP	M2i5bHNCVkeHUh?=
AU565	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PFcWlEPTB;MD60NlQ3QCEQvF2=	NY\INnpUW0GQR1XS
FADU	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3[xbWlEPTB;MD60NlY1QSEQvF2=	M3zsWXNCVkeHUh?=
OS-RC-2	NGrje3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13VbWlEPTB;MD60N\|A5OyEQvF2=	MWLTRW5ITVJ?
CAMA-1	NW\ZfYdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTx[JE1UUN3ME2wMlQ{PjJ4IN88US=>	M2[5Z3NCVkeHUh?=
MONO-MAC-6	Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\2XIJEUUN3ME2wMlQ{QDR7IN88US=>	MWrTRW5ITVJ?
LB831-BLC	M134bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fqOGlEPTB;MD60OFM4OSEQvF2=	NITsXGhUSU6JRWK=
SW982	NUfqWld2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2H2Z2lEPTB;MD60OFUzQCEQvF2=	NGXnVWlUSU6JRWK=
SCC-3	NGXSb\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LwV2lEPTB;MD60OFU4QSEQvF2=	M1zVfHNCVkeHUh?=
C32	M{D0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHCWnZKSzVyPUCuOFUzOjlizszN	MUfTRW5ITVJ?
BFTC-909	M1HPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2i1bWlEPTB;MD60OVI6QSEQvF2=	M1TwWXNCVkeHUh?=
MEG-01	M1jVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nNTWlEPTB;MD60OVM4OyEQvF2=	MVHTRW5ITVJ?
M14	MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mne2TWM2OD1yLkS1PVc6KM7:TR?=	MkL5V2FPT0WU
MPP-89	M2ixbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTINpJKSzVyPUCuOFYzPTZizszN	Mk\UV2FPT0WU
HCC1937	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfPSoZZUUN3ME2wMlQ3Ozh2IN88US=>	M2T2Z3NCVkeHUh?=
SW837	NGPpOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;OfmxKSzVyPUCuOFY4OjJizszN	MkG3V2FPT0WU
DU-145	MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwNE[3Nlkh\|ryP	NXzPNFhEW0GQR1XS
LB996-RCC	MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVH3[YplUUN3ME2wMlQ4ODV2IN88US=>	NELkeGtUSU6JRWK=
C8166	NVrBdW0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjveopKSzVyPUCuOFc1KM7:TR?=	MXrTRW5ITVJ?
MOLT-4	MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwNEe3N\|Qh\|ryP	NFTGbY1USU6JRWK=
DMS-53	NX\MWZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HNe2lEPTB;MD60O\|gxQSEQvF2=	Ml71V2FPT0WU
TE-5	M3\4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nn[GlEPTB;MD60PFMxPSEQvF2=	M4D3R3NCVkeHUh?=
KYSE-520	M{fyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvubFVKSzVyPUCuOFg{PDNizszN	NXrlWJlMW0GQR1XS
Detroit562	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlviTWM2OD1yLkS4PFYh\|ryP	MVvTRW5ITVJ?
SIMA	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWe0b3JHUUN3ME2wMlQ6PDF5IN88US=>	MVXTRW5ITVJ?
NCI-H1651	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwNEm2O{DPxE1?	NX35OHMxW0GQR1XS
HCC1599	Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\wW25oUUN3ME2wMlQ6QTV3IN88US=>	NVP2dHI{W0GQR1XS
ABC-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFv5b5NKSzVyPUCuOVA1QTZizszN	MYTTRW5ITVJ?
CAL-33	NFryTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUS0O\|RSUUN3ME2wMlUxQDR2IN88US=>	NUf2WIFGW0GQR1XS
OPM-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwNUC5N\|ch\|ryP	NYm3So0{W0GQR1XS
RPMI-7951	NFu4OnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDmTWM2OD1yLkWwPVU4KM7:TR?=	NWr4dGNRW0GQR1XS
HT-1080	MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTBTWM2OD1yLkWxNVE6KM7:TR?=	NG\6VHZUSU6JRWK=
LC4-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPtXmhKSzVyPUCuOVE1ODNizszN	M3[5TnNCVkeHUh?=
OVCAR-3	MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\6[ng{UUN3ME2wMlUyPTdizszN	NV[4O5V[W0GQR1XS
CAPAN-1	NEjiUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjTVY9KSzVyPUCuOVIzQDhizszN	MorJV2FPT0WU
SK-OV-3	M2O3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXuNHVrUUN3ME2wMlUzPDN2IN88US=>	NHHsXnhUSU6JRWK=
HuP-T3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorSTWM2OD1yLkWyPFI4KM7:TR?=	NHHBS\|hUSU6JRWK=
NCI-H838	MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwNUK4OFkh\|ryP	M3Pn[nNCVkeHUh?=
K5	M36wVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwNUOyNFEh\|ryP	NGC1OYdUSU6JRWK=
CAL-72	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XFWGlEPTB;MD61N\|M5PyEQvF2=	MVjTRW5ITVJ?
NH-12	M3frXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jkfGlEPTB;MD61N\|k2QSEQvF2=	M3i3U3NCVkeHUh?=
SNB75	M4f6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;ORmlEPTB;MD61OVc{KM7:TR?=	M4LQOnNCVkeHUh?=
BPH-1	NU\WWHhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3oPXBtUUN3ME2wMlU3OzR2IN88US=>	MVjTRW5ITVJ?
NOMO-1	NVXTZncxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvZemRKSzVyPUCuOVY{PzJizszN	NVfYcmsxW0GQR1XS
G-402	M13mbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTWVIFKSzVyPUCuOVY1QTlizszN	NFzl[I9USU6JRWK=
NCI-H2052	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vXfmlEPTB;MD61Olc1OSEQvF2=	M4j5fXNCVkeHUh?=
RCM-1	NVPzVXU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwNUexOlYh\|ryP	NGXMUYxUSU6JRWK=
COR-L279	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEW3UmNKSzVyPUCuOVcyQDVizszN	M13UfnNCVkeHUh?=
A253	MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTBwNUe1NlUh\|ryP	M4[xVnNCVkeHUh?=
SK-MM-2	NHHaR5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPBTWM2OD1yLkW3Olc6KM7:TR?=	MYLTRW5ITVJ?
NCI-H1703	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzQTWM2OD1yLkW5OFI4KM7:TR?=	MX;TRW5ITVJ?
UACC-257	M1;oOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwNUm0PFch\|ryP	MV;TRW5ITVJ?
KALS-1	M4rSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUW0eGw2UUN3ME2wMlYxODFzIN88US=>	M2\pdHNCVkeHUh?=
ES5	NEnLeIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVL6[5UxUUN3ME2wMlYxPDhizszN	NFjhdnBUSU6JRWK=
MHH-CALL-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDScI56UUN3ME2wMlYxQDh6IN88US=>	MYLTRW5ITVJ?
ChaGo-K-1	M1vkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rHNWlEPTB;MD62NVIzQSEQvF2=	Ml\QV2FPT0WU
TGBC1TKB	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTTUIdKSzVyPUCuOlE6QCEQvF2=	MVrTRW5ITVJ?
KU-19-19	NHX1eo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvUTWM2OD1yLk[0OVg3KM7:TR?=	NIfSb5BUSU6JRWK=
COLO-684	MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUD4dGxMUUN3ME2wMlY2PjFzIN88US=>	M4nVXHNCVkeHUh?=
LS-1034	NIfPZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3kcpllUUN3ME2wMlY2QDF7IN88US=>	NEfZZYdUSU6JRWK=
RT-112	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLTTWM2OD1yLk[2OVg4KM7:TR?=	NGLKdnRUSU6JRWK=
Capan-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LqRmlEPTB;MD62OlYzOiEQvF2=	MUjTRW5ITVJ?
HSC-4	Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojXTWM2OD1yLk[2Olk5KM7:TR?=	NX\y[VBDW0GQR1XS
COLO-824	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLB[Xd5UUN3ME2wMlY4QDJ\|IN88US=>	M1XxUHNCVkeHUh?=
NCI-H2170	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLsell[UUN3ME2wMlY5OjV6IN88US=>	MWXTRW5ITVJ?
GDM-1	Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvwTWM2OD1yLk[4OFk1KM7:TR?=	NHX1V4NUSU6JRWK=
KP-4	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEexbHJKSzVyPUCuOlk2PzNizszN	MofCV2FPT0WU
VA-ES-BJ	MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfGXYRQUUN3ME2wMlY6QTh4IN88US=>	NHLiZpJUSU6JRWK=
KM-H2	NUL3bHZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHqeYxKSzVyPUCuO\|AxQTFizszN	NHLMT5RUSU6JRWK=
HH	NInmUWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zPPGlEPTB;MD63NFY3OiEQvF2=	M1L4fHNCVkeHUh?=
DK-MG	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LJWGlEPTB;MD63NVAyPiEQvF2=	M1vsN3NCVkeHUh?=
VM-CUB-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjJXVVKSzVyPUCuO\|EzPTlizszN	MnLFV2FPT0WU
COLO-829	NGWwT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDtTWM2OD1yLkexPVg2KM7:TR?=	NHrWN\|JUSU6JRWK=
OMC-1	M4nDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fiN2lEPTB;MD63NlExPCEQvF2=	MnXkV2FPT0WU
NB12	MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwN{K1NFQh\|ryP	MWXTRW5ITVJ?
NCI-H28	M13mUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TTNWlEPTB;MD63OFA5OyEQvF2=	NIHzOVFUSU6JRWK=
A673	NEXHR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;aemlEPTB;MD63OVE4PyEQvF2=	MmfKV2FPT0WU
LB2241-RCC	MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LjVGlEPTB;MD63OlA5PyEQvF2=	NInTVG5USU6JRWK=
CCRF-CEM	NX33RnI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInCOVdKSzVyPUCuO\|cxPTJizszN	MmHsV2FPT0WU
NCI-H510A	NYTnfFRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2P0OGlEPTB;MD63O\|E5PiEQvF2=	MnnzV2FPT0WU
SW48	M4rBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7RTWM2OD1yLke3N\|M{KM7:TR?=	MVfTRW5ITVJ?
NCI-H2081	M33kRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7xUI9KSzVyPUCuO\|gyPDdizszN	M372UXNCVkeHUh?=
RMG-I	NYXXbnk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFP3eFhKSzVyPUCuO\|gzOTJizszN	MoO1V2FPT0WU
LU-99A	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwN{i0NVMh\|ryP	Mli2V2FPT0WU
KP-N-YS	M4fKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwN{i5NlEh\|ryP	NYfZVXBkW0GQR1XS
MDA-MB-231	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrzdmhKSzVyPUCuPFAyOzFizszN	MmDPV2FPT0WU
U031	M4fsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPtWZJKSzVyPUCuPFE1OjNizszN	NV21Zpc2W0GQR1XS
EVSA-T	NGizfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzJTWM2OD1yLkixOlczKM7:TR?=	NXGyS4xMW0GQR1XS
MDA-MB-157	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTBwOEKyO\|Eh\|ryP	NGHlS\|ZUSU6JRWK=
EHEB	NVXHUGV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjBTWM2OD1yLkiyNlc3KM7:TR?=	NX\tRoxbW0GQR1XS
KINGS-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW[xfWh2UUN3ME2wMlgzPTV3IN88US=>	MnfuV2FPT0WU
23132-87	MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwOEK4OFMh\|ryP	M{DMdXNCVkeHUh?=
EFO-21	NH;3eoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rYfmlEPTB;MD64OFA5QSEQvF2=	MmX2V2FPT0WU
DOK	NEDsT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnSyTWM2OD1yLki0PEDPxE1?	NW\LbXhIW0GQR1XS
NCI-H2171	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjnepVCUUN3ME2wMlg1QTZizszN	NXXoNXg1W0GQR1XS
NCI-SNU-5	NWW0Oow1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jqdGlEPTB;MD64OVU4KM7:TR?=	MXPTRW5ITVJ?
SK-N-DZ	NWmzXog6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\OZndRUUN3ME2wMlg2QTR\|IN88US=>	Ml:5V2FPT0WU
SNU-C2B	NIjtfJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvuTWM2OD1yLki2PFAyKM7:TR?=	NE\hTWhUSU6JRWK=
CP66-MEL	NXfLbY9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjyNllKSzVyPUCuPFcyOSEQvF2=	MUjTRW5ITVJ?
SN12C	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfQc3lKSzVyPUCuPFg3OzdizszN	NWfnfYdsW0GQR1XS
A172	NGLZb3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nnOWlEPTB;MD64PFY6QCEQvF2=	Mn;WV2FPT0WU
NCI-H2347	NX;lVG1KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwOEi3OVMh\|ryP	NIjqbJZUSU6JRWK=
NCI-H2228	NHTwZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDuSI1bUUN3ME2wMlg6OzN7IN88US=>	MXjTRW5ITVJ?
SNU-387	M1zEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTU[\|U4UUN3ME2wMlkxOjZ2IN88US=>	NYPTcVh5W0GQR1XS
SK-MEL-24	M2Dsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1r3[mlEPTB;MD65NVM1PCEQvF2=	NULhNINkW0GQR1XS
MDA-MB-468	NIi1SXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwOUG3N{DPxE1?	NFv1dWRUSU6JRWK=
NCI-H1694	Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXnUoxKSzVyPUCuPVE5PzZizszN	NIjiNmhUSU6JRWK=
CCF-STTG1	MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jpeWlEPTB;MD65NlY{PyEQvF2=	M{HNdnNCVkeHUh?=
K052	M4PmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PDbGlEPTB;MD65OFA1PyEQvF2=	MVfTRW5ITVJ?
NCI-H446	M{nlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIO3cXpKSzVyPUCuPVUxOSEQvF2=	NIDvO4dUSU6JRWK=
MFE-280	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlj3TWM2OD1yLkm2NlkyKM7:TR?=	NVSz[3V[W0GQR1XS
KU812	MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXkT3ZKSzVyPUCuPVk{QDlizszN	NYTSUWc1W0GQR1XS
MDA-MB-361	NY\OSWRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3noTWlEPTB;MD65PVc4PyEQvF2=	NXvlPXdLW0GQR1XS
Raji	MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTFwMEKyOlch\|ryP	MVnTRW5ITVJ?
TE-6	NWXvVVROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjPeWVKSzVyPUGuNFM2PjZizszN	NUPGWYVOW0GQR1XS
CAL-148	MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37qR2lEPTB;MT6wOFQ1OyEQvF2=	NVTUUpN[W0GQR1XS
NCI-H1963	M4raXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHL[HlKSzVyPUGuNFQ2PTNizszN	MofXV2FPT0WU
SK-N-AS	NYXWZWZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jQPGlEPTB;MT6wOFY5PSEQvF2=	NFvPV5JUSU6JRWK=
RERF-LC-MS	MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rZeGlEPTB;MT6wOlM1QSEQvF2=	M1:yUHNCVkeHUh?=
BEN	MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrYb2VKSzVyPUGuNFcyOzdizszN	Mo\nV2FPT0WU
CAS-1	NFPR[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;yRWpPUUN3ME2xMlA6OTJ\|IN88US=>	NVnsV5g1W0GQR1XS
SW780	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGr2RohKSzVyPUGuNFkyQDFizszN	M1rUdHNCVkeHUh?=
LU-65	NH72VVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnFbYFKSzVyPUGuNFk1OSEQvF2=	MWjTRW5ITVJ?
D-283MED	NWXnXpNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DkPWlEPTB;MT6xNlI4OiEQvF2=	MlLuV2FPT0WU
HCC2157	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHv1cY1KSzVyPUGuNVM3PDJizszN	NH7tVpFUSU6JRWK=
RCC10RGB	NIXhNI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFv5UmVKSzVyPUGuNVQxODZizszN	NUjTdnR4W0GQR1XS
PLC-PRF-5	M4G2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEToV2RKSzVyPUGuNVUzOjlizszN	NXrOW4NHW0GQR1XS
H4	NXTaV3k6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTFwMUW0N\|kh\|ryP	MYfTRW5ITVJ?
TUR	M1GzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\jTWM2OD1zLkG1O\|UzKM7:TR?=	NIDxVGxUSU6JRWK=
NCI-H2141	NWrB[G4zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPwcHFDUUN3ME2xMlE5QTR4IN88US=>	MVnTRW5ITVJ?
PFSK-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfnTWM2OD1zLkKwOVMzKM7:TR?=	M3\tWnNCVkeHUh?=
SK-MEL-28	M1\aZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTFwMkOyNlEh\|ryP	NWe5Zm1wW0GQR1XS
SCC-9	M1Wxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnQd2ZFUUN3ME2xMlI{PjZ3IN88US=>	NE\HWmVUSU6JRWK=
T47D	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTFwMkO2PVYh\|ryP	M{HpcnNCVkeHUh?=
TCCSUP	NYHxfVdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDBcWlKSzVyPUGuNlUxOjlizszN	NHLF[XhUSU6JRWK=
SU-DHL-1	MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3UTWM2OD1zLkK1NVE5KM7:TR?=	M4\nZXNCVkeHUh?=
HL-60	M2[3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLPTIFKSzVyPUGuNlU2QDhizszN	NG\ncmtUSU6JRWK=
NCI-H1436	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFf1dYdKSzVyPUGuNlYyPDlizszN	NVf0[FdRW0GQR1XS
DMS-114	NYn4UIZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnm0TWM2OD1zLkK2OlMzKM7:TR?=	NGOzN4xUSU6JRWK=
BOKU	NVPHcmY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWOzUnZGUUN3ME2xMlI5ODl3IN88US=>	M{fDcHNCVkeHUh?=
MS-1	NYK1UJpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTFwMkmwOlkh\|ryP	MWXTRW5ITVJ?
NCI-H661	NYKyXFBZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvZWWZKSzVyPUGuN\|A1PzhizszN	NU\pOY1nW0GQR1XS
HT-3	NV;MSmd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHSTWM2OD1zLkOwOVI6KM7:TR?=	NGnt[YxUSU6JRWK=
CAL-54	NWTpTHc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTFwM{C3NlUh\|ryP	MmT3V2FPT0WU
SW1463	MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUG1NWpHUUN3ME2xMlMyQDd{IN88US=>	NF76XWpUSU6JRWK=
COLO-668	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{T2XGlEPTB;MT6zN\|A2PiEQvF2=	NUXjZXB4W0GQR1XS
PANC-08-13	MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTFwM{O4NFMh\|ryP	M{\IZXNCVkeHUh?=
BB49-HNC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\pSGlEPTB;MT6zOFAyKM7:TR?=	M3juUXNCVkeHUh?=
M059J	Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFu3VXlKSzVyPUGuN\|U5OzJizszN	MkX1V2FPT0WU
NCCIT	M2C1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTCTWM2OD1zLkO3PVg5KM7:TR?=	MVTTRW5ITVJ?
LN-405	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILXNHRKSzVyPUGuN\|kzPjRizszN	MYrTRW5ITVJ?
UMC-11	M1rrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3J[ZM5UUN3ME2xMlM6QTl4IN88US=>	M3vZbHNCVkeHUh?=
NB5	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvNfFhmUUN3ME2xMlQyOjJ5IN88US=>	MoXvV2FPT0WU
TE-441-T	M2Lxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnqe\|ZKSzVyPUGuOFI5OTdizszN	M3jROnNCVkeHUh?=
ME-180	NHrkeIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HRWGlEPTB;MT60OFM6OiEQvF2=	NEH2WFVUSU6JRWK=
HCC70	M1;oVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLjTWM2OD1zLkS2NFk3KM7:TR?=	M{TBcHNCVkeHUh?=
no-10	NUKyUY9ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVKzdFlMUUN3ME2xMlQ3OThzIN88US=>	NXm4N3NRW0GQR1XS
JEG-3	MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XOTmlEPTB;MT61NFE{OiEQvF2=	Mn3KV2FPT0WU
no-11	NFexUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnpTWM2OD1zLkWwPFgzKM7:TR?=	MXrTRW5ITVJ?
CHP-126	NVTYfYNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnNTHFtUUN3ME2xMlU3PjlzIN88US=>	NXq3eW9jW0GQR1XS
EGI-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTFwNUiwNlUh\|ryP	M{HRdHNCVkeHUh?=
D-392MG	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXH6TFhRUUN3ME2xMlU6PjNizszN	NXHXWZhqW0GQR1XS
RT4	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWr6XlI5UUN3ME2xMlU6PjN5IN88US=>	MmPiV2FPT0WU
A204	NFixfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkiwTWM2OD1zLkW5PFAyKM7:TR?=	MlfPV2FPT0WU
NCI-H1304	NUjKVZU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LXXWlEPTB;MT62N\|U6OSEQvF2=	NGHveG1USU6JRWK=
Becker	M333W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmS3TWM2OD1zLk[0NlQyKM7:TR?=	Ml23V2FPT0WU
OE19	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTFwNkW1NVgh\|ryP	NVLxc3JYW0GQR1XS
EKVX	NEPhfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEX4c4dKSzVyPUGuOlU3OThizszN	M3TlbXNCVkeHUh?=
KLE	NYDCWI9KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTFwNkW3NVQh\|ryP	M17LdXNCVkeHUh?=
K-562	NFr6eGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPuTWM2OD1zLk[3NFM4KM7:TR?=	M1jlUHNCVkeHUh?=
MDA-MB-175-VII	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2i5WGlEPTB;MT62PFk6PyEQvF2=	M{XkRXNCVkeHUh?=
NCI-H716	MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYT5TYJ7UUN3ME2xMlY6OzB2IN88US=>	M3XlN3NCVkeHUh?=
Caov-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTFwNkm0NVMh\|ryP	NE\IN2FUSU6JRWK=
HCC1187	NV7xVmhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;4WoZKSzVyPUGuO\|A2PDVizszN	M4OzNnNCVkeHUh?=
CAKI-1	M{LmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzTPWp1UUN3ME2xMlczOjl{IN88US=>	NGrmVlNUSU6JRWK=
MOLT-16	NUXtVHdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrUbYVKSzVyPUGuO\|M{ODdizszN	MkGwV2FPT0WU
PC-3	NV7lSGFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moi4TWM2OD1zLke1NFgh\|ryP	MVHTRW5ITVJ?
DV-90	M{\BcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTFwN{W1PFUh\|ryP	NV3YPWhpW0GQR1XS
RXF393	NEXtbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTFwN{eyPVQh\|ryP	NU\TU\|hjW0GQR1XS
SK-NEP-1	M37FPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXjTWM2OD1zLkiyN\|M6KM7:TR?=	MnLVV2FPT0WU
HCC1419	NEmybo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHlTWM2OD1zLkiyOlkzKM7:TR?=	Mn35V2FPT0WU
BV-173	NVvifHY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXL0R21VUUN3ME2xMlgzQTl3IN88US=>	M1LzW3NCVkeHUh?=
MKN7	M3jGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETaUnJKSzVyPUGuPFkzOiEQvF2=	NFzh[WFUSU6JRWK=
LAN-6	Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\aXopKSzVyPUGuPFk2PTNizszN	MknDV2FPT0WU
Mo-T	NXjwSFk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2f0bGlEPTB;MT65NFA{QSEQvF2=	MWTTRW5ITVJ?
HCC1395	NVq4cXpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjaboFKSzVyPUGuPVI5PjNizszN	NFXrflVUSU6JRWK=
HC-1	NFfuOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTFwOUO0O{DPxE1?	NIPhe21USU6JRWK=
HPAF-II	NVjRUFF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTFwOUS0NVgh\|ryP	MlPVV2FPT0WU
CPC-N	MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHPbJdwUUN3ME2xMlk5ODB{IN88US=>	NV3hSFFmW0GQR1XS
MKN45	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTFwOUmxNVkh\|ryP	NYC3SWg3W0GQR1XS
NCI-H1693	Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTJwMEC0N\|Mh\|ryP	NFKzNZFUSU6JRWK=
SHP-77	MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTkR2ZKSzVyPUKuNFA2OzNizszN	NInGS5BUSU6JRWK=
NCI-H1522	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;3fWlEPTB;Mj6wNVczPCEQvF2=	NWj2[3ZVW0GQR1XS
SW1573	Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPPTWM2OD1{LkCyNkDPxE1?	NHu3V4hUSU6JRWK=
DBTRG-05MG	NFP2cHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTJwME[wPFch\|ryP	NHH1R5pUSU6JRWK=
SCC-4	NFK1eodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTJwMUSzNUDPxE1?	M1vt[HNCVkeHUh?=
DMS-153	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTJwMU[2Olgh\|ryP	M4rkTHNCVkeHUh?=
MDA-MB-415	NWDW[VN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\lWVNKSzVyPUKuNVc2OiEQvF2=	MoWzV2FPT0WU
NCI-H2126	M2LYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1z6e2lEPTB;Mj6yNlg5QCEQvF2=	MnzDV2FPT0WU
MDA-MB-453	M2PISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;yTWM2OD1{LkKzN\|Ih\|ryP	M1PwO3NCVkeHUh?=
U-87-MG	NInsW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTJwMki1PVIh\|ryP	Mk\VV2FPT0WU
LNCaP-Clone-FGC	NX:2[5pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1joSWlEPTB;Mj6zNFExOiEQvF2=	MkLPV2FPT0WU
NCI-H1581	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzU[WNKSzVyPUKuN\|IyODVizszN	M2LaTXNCVkeHUh?=
BC-3	MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTubmdPUUN3ME2yMlM3PTB7IN88US=>	NHO2XHVUSU6JRWK=
HCC38	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTJwM{i0OFch\|ryP	M13kVXNCVkeHUh?=
HCC2218	MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1y4[2lEPTB;Mj60NFgxQSEQvF2=	M4i3NXNCVkeHUh?=
RO82-W-1	M2DkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3Ye5p5UUN3ME2yMlQyOjVizszN	MoLwV2FPT0WU
C2BBe1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYCySod3UUN3ME2yMlQyPTd6IN88US=>	NHzjUHZUSU6JRWK=
LAMA-84	M2fCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlruTWM2OD1{LkW3N\|Y5KM7:TR?=	NFnscXNUSU6JRWK=
GMS-10	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LrW2lEPTB;Mj61O\|YyOSEQvF2=	MV3TRW5ITVJ?
GCT	Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXBUXJKSzVyPUKuOVg3QTRizszN	MnTLV2FPT0WU
SK-CO-1	MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PtWGlEPTB;Mj62NVY3KM7:TR?=	MVLTRW5ITVJ?
NCI-H526	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jpUGlEPTB;Mj62N\|Q2KM7:TR?=	MWPTRW5ITVJ?
SW1088	Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPpV\|lOUUN3ME2yMlc4QDN7IN88US=>	NH7TboxUSU6JRWK=
HT55	NWXGc3NRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYj3SVJTUUN3ME2yMlc5Pjl3IN88US=>	MoHrV2FPT0WU
NB10	M{XUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnxTWM2OD1{LkixO\|Q5KM7:TR?=	NF\1OnVUSU6JRWK=
UACC-893	MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTJwOEW3OFkh\|ryP	MmnpV2FPT0WU
NCI-H1618	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nvcmlEPTB;Mj64PFE2OyEQvF2=	NETLTHJUSU6JRWK=
NCI-H1092	NF7FOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfsTWFKSzVyPUOuNFc5OTJizszN	M2KwPHNCVkeHUh?=
SBC-1	NI[4b5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HHVmlEPTB;Mz6wPFU2OyEQvF2=	MUPTRW5ITVJ?
NCI-H1623	NYXVcHpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHFZmNKSzVyPUOuNFk{PCEQvF2=	NX7VNpNQW0GQR1XS
SiHa	MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LmfWlEPTB;Mz6xNVk4PyEQvF2=	MUXTRW5ITVJ?
D-263MG	MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;tVlc4UUN3ME2zMlE1Pzh6IN88US=>	M374VHNCVkeHUh?=
NCI-H1573	MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1W4OGlEPTB;Mz6xPVY1OSEQvF2=	M4D0[XNCVkeHUh?=
NCI-H82	MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;wUVRKSzVyPUOuN\|Q1OzlizszN	NU\zVlg4W0GQR1XS
NCI-H2196	NXSwR\|JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;lTWM2OD1\|LkO1NFA5KM7:TR?=	NUDFd5RrW0GQR1XS
MFM-223	NEfqbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn[5TWM2OD1\|LkO3N\|UyKM7:TR?=	MX7TRW5ITVJ?
COLO-678	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTNwM{ixPFYh\|ryP	NH3rZm5USU6JRWK=
EW-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfwcnRKSzVyPUOuOFA6PSEQvF2=	NXHIRnpiW0GQR1XS
MHH-NB-11	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrNdYFKSzVyPUOuOFQxPjlizszN	MlnaV2FPT0WU
EM-2	Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTNwNkO5PEDPxE1?	NV;tW\|QxW0GQR1XS
FTC-133	MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTNwNkW0OVgh\|ryP	M2C5OnNCVkeHUh?=
NCI-H209	NY\hPHRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTNwNke2OVMh\|ryP	NEmydlBUSU6JRWK=
TGBC24TKB	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTNwNkizOVUh\|ryP	MWrTRW5ITVJ?
LC-1F	MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUWz[JZMUUN3ME2zMlcyPzZ2IN88US=>	MVTTRW5ITVJ?
C-4-II	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjrU21KSzVyPUOuO\|U3PDNizszN	MknqV2FPT0WU
NCI-H1650	M3f4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzPW4RvUUN3ME2zMlc5PDV3IN88US=>	MWLTRW5ITVJ?
JVM-2	NGnIRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWf3SGdTUUN3ME2zMlk{PjN7IN88US=>	Mlj2V2FPT0WU
CaR-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTNwOUe2NVch\|ryP	NXf0OpZnW0GQR1XS
MDA-MB-134-VI	MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo[wTWM2OD12LkCyPVUzKM7:TR?=	NWLx[pBpW0GQR1XS
NCI-H719	NELNcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\WeGpKSzVyPUSuNVU{QDhizszN	MX\TRW5ITVJ?
GOTO	Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jiWWlEPTB;ND6yPVcxPSEQvF2=	NVOzW5F7W0GQR1XS
NCI-N87	M36zUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1W2NmlEPTB;ND6zPFgzOSEQvF2=	MY\TRW5ITVJ?
NB6	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3MTWM2OD12LkSyOVA6KM7:TR?=	NULqeY8{W0GQR1XS
DSH1	NVLle2ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPMV4tKSzVyPUSuOFcyOTZizszN	MmrGV2FPT0WU
BT-20	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvFTWM2OD12LkS5NFAzKM7:TR?=	M3nEZXNCVkeHUh?=
NCI-H1882	NXrU[odsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWmzfYNZUUN3ME20MlUxPTdizszN	NYTtSmV7W0GQR1XS
WM-115	M3\uVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DneWlEPTB;ND61NFg5OSEQvF2=	MVXTRW5ITVJ?
SKG-IIIa	NVzWRlZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm[xTWM2OD12Lk[3O\|ch\|ryP	MYDTRW5ITVJ?
NCI-H69	MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7BfppqUUN3ME20MlcxOjd3IN88US=>	M2HzTnNCVkeHUh?=
MSTO-211H	NYrlTWp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrpT416UUN3ME20Mlg{PTZ3IN88US=>	Ml2wV2FPT0WU
Mewo	Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTRwOU[zNVMh\|ryP	NEH3cnZUSU6JRWK=
GI-ME-N	NHzXR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nRUGlEPTB;NT6wNFUxQSEQvF2=	M{izOHNCVkeHUh?=
T98G	NEm2ZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjYRZdKSzVyPUWuNFY2ODhizszN	NUD2ToJCW0GQR1XS
ECC4	NXK4WlF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mny5TWM2OD13LkC5N\|czKM7:TR?=	NID3To5USU6JRWK=
EW-11	NVnmZ5pbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXn0fJRqUUN3ME21MlE5ODl7IN88US=>	MUjTRW5ITVJ?
COLO-800	M{XXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfNPFNKSzVyPUWuNVk{PDlizszN	MWHTRW5ITVJ?
NCI-H1755	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zYeGlEPTB;NT6yN\|AzPyEQvF2=	M1vtc3NCVkeHUh?=
KMS-12-PE	NYTzb3E5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPSOVFKSzVyPUWuN\|UxQDVizszN	MYXTRW5ITVJ?
HCC1954	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvsTWM2OD13Lki1PVcyKM7:TR?=	Mlj6V2FPT0WU
NCI-H187	M{fzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrqNnFyUUN3ME21MlkzQTh7IN88US=>	NWe5NGNCW0GQR1XS
LU-165	M{HJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4r4WmlEPTB;NT65PVAxOiEQvF2=	M1nMbXNCVkeHUh?=
YAPC	M2qxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHPTWM2OD13Lkm5NFY5KM7:TR?=	NWPYS3QxW0GQR1XS
LU-139	MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFq2fHBKSzVyPU[uNFg{PjhizszN	NFu3XIlUSU6JRWK=
D-502MG	M3X3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2mzTGlEPTB;Nj6zNlA1PyEQvF2=	NWPXc\|RIW0GQR1XS
IST-SL1	M1W1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlu4TWM2OD14LkWzPVQ5KM7:TR?=	NUH2OJFVW0GQR1XS
DG-75	MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HYe2lEPTB;Nj64PFc5PiEQvF2=	Mme0V2FPT0WU
NCI-H1155	MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTZwOUW1PFEh\|ryP	MlSwV2FPT0WU
EFE-184	MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPNUmp5UUN3ME23MlMyPjl3IN88US=>	MYPTRW5ITVJ?
AsPC-1	NGHkVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jxSGlEPTB;Nz60PFgxPyEQvF2=	NGruV3ZUSU6JRWK=
SW948	M4KxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PFeGlEPTB;Nz61PFM6PSEQvF2=	NVzFb\|ZiW0GQR1XS
NCI-H524	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXIUoM3UUN3ME25MlU5PjJ6IN88US=>	MYXTRW5ITVJ?
KOSC-2	NYHtOIxzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHpTWM2OD17Lk[yPFM1KM7:TR?=	MnzmV2FPT0WU
T-24	NXK1VVA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4f3OWlEPTB;OT65OFQyPSEQvF2=	NGLtU\|FUSU6JRWK=
NCI-H748	NUK0VYdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PXemlEPTB;MUCuOlM6PyEQvF2=	NV7sNYh5W0GQR1XS
NCI-H23	NWTGS\|VjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfqOpJ6UUN3ME2xNE43PDR{IN88US=>	MkfMV2FPT0WU
UACC-812	NULPZZB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTFzLkexO{DPxE1?	NEPnboRUSU6JRWK=
SCLC-21H	MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTF{LkG1OVEh\|ryP	NIr2SnNUSU6JRWK=
NCI-SNU-16	MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTF\|LkGyOVgh\|ryP	M{PCN3NCVkeHUh?=
HD-MY-Z	NVn0U\|JVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoC3TWM2OD1zND62N\|Y{KM7:TR?=	NITHOZpUSU6JRWK=
SK-N-FI	NUf2RVJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrxTWM2OD1zND64PVEzKM7:TR?=	MnfXV2FPT0WU
LB647-SCLC	MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLjTWM2OD1zNT63NVk2KM7:TR?=	MmjEV2FPT0WU
NCI-H345	NEPZeJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LCTmlEPTB;MUeuN\|Q{KM7:TR?=	NWHGd2hOW0GQR1XS
NCI-H1563	NFTyZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHuTWM2OD1zOD63OlAyKM7:TR?=	MUXTRW5ITVJ?
RL	M4jTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofpTWM2OD1{MT6yOlU3KM7:TR?=	M4jIRnNCVkeHUh?=
KY821	NHrPeoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjqNIJCUUN3ME2yNk4xPTV\|IN88US=>	MV7TRW5ITVJ?
JVM-3	MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnFcmZKSzVyPUK1MlA1OTNizszN	NYrqPIp[W0GQR1XS
NCI-H1793	NEW0fHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{S0OGlEPTB;MkiuOVQ6QSEQvF2=	NEH4dpRUSU6JRWK=
LU-134-A	NEC0bIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;WTWM2OD1\|MD6yNFM4KM7:TR?=	NFrjPWdUSU6JRWK=
NCI-H1395	Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnVW5lKSzVyPUOyMlI1OzFizszN	MYnTRW5ITVJ?
NCI-H1993	NEOyNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fCbmlEPTB;M{KuPFIyQCEQvF2=	M1H0fnNCVkeHUh?=
P31-FUJ	M3K0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXK[5VKSzVyPUOzMlQ5QTlizszN	M4PwNnNCVkeHUh?=
LS-513	MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnewTWM2OD1\|NT64PFc6KM7:TR?=	Mk\HV2FPT0WU
SK-MEL-1	NH;GVHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\rTnhpUUN3ME20NE4{PDl7IN88US=>	MlfmV2FPT0WU
SW684	MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTR\|Lkm2OlEh\|ryP	NUTOWG9UW0GQR1XS
COR-L88	NYLpfnJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHOUlBKSzVyPUS0MlA3PjVizszN	M1fXZnNCVkeHUh?=
NCI-H889	NIfYOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLGcIFUUUN3ME20OU4xODh5IN88US=>	M3m2b3NCVkeHUh?=
TALL-1	NVfLPYliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvzTWM2OD12Nj6xNVk6KM7:TR?=	MlLBV2FPT0WU
KARPAS-299	Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NISxfHdKSzVyPUS3MlE6QTNizszN	MlW3V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cyclin D1 / p27 Kip1 ; PubMed: 28382170 Theranostics Western blotting showed that Obatoclax impacted cell cycle distribution through lowering cyclin D1 in K1 cells but in BCPAP cells, it impacted expression of p27 Kip1 rather than cyclin D1. p-Cyclin D1 ; PubMed: 28035994 Int J Mol Sci Cell line-dependent effect of obatoclax on cyclin D1 T286 phosphorylation. HCT116, HT-29, and LoVo cells were subject to 24 h-treatment with obatoclax (200 nM), followed by immunoblotting to evaluate the levels of threonine 286 (T286)-phosphorylated cyclin D1 (p-Cyclin D1) at indicated time points. α-Tubulin levels served as equal loading control; p-GSK3β / GSK3β / p-ERK / ERK / p-p38 / p38; PubMed: 28035994 Int J Mol Sci Obatoclax inhibits GSK3β but activates p38 (MAPK), while barely affecting ERK1/2 activity in HT-29 cells. HT-29 cells were exposed to 200 nM of obatoclax for 24 h. The status of activation of GSK3β, ERK1/2, and p38(MAPK) at indicated time points was determined by immunoblotting for corresponding phosphorylation. Specifically, serine 9-phosphorylation of GSK3β (p-GSK3β) reveals inhibition of GSK3β activity, whereas dual phosphorylation at threonine 202/tyrosine 204 of ERK1/2 (p-ERK1/2) and threonine 180/tyrosine 182 of p38 MAPK (p-p38) indicate activation of ERK1/2 and p38(MAPK), respectively. α-Tubulin levels served as equal loading control;	28382170 28035994
Growth inhibition assay	Cell proliferation ; PubMed: 28035994 Int J Mol Sci Obatoclax inhibits colorectal cancer cell proliferation. Human colorectal carcinoma cell lines HCT116, HT-29, and LoVo cells were treated with obatoclax (0, 50, 100, 200 nM) for 24, 48, and 72 h. The numbers of cells at each time point were counted using a Neubauer chamber. Data were presented as the percentage relative to the drug-untreated control. Cell viability; PubMed: 21368880 Cell Death Dis H727 NSCLC cells are resistant to obatoclax. H727 and H1975 NSCLC cells were treated with obatoclax at the indicated doses for 48 (left) or 72 h (right), and the viability of cells determined by ViaLight assay. The EC50 values of cells at 48 h were; H1975 267 nM; H727 3.2 μM. The EC50 values of cells at 72 h were; H1975 66 nM; H727 621 nM. Data are expressed as mean±S.D.	28035994 21368880

In vivo

Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Bcl-2 Binding affinity calculation: A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. ^[4] As a control in determining the reliability of the calculation, predicted binding affinities K_i) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:^[2]	- Collapse Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) Concentrations: ~10 μM Incubation Time: 48-72 hours Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 10⁴ per well for HMCLs or 5~10 × 10³ for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used. Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg Administration: Administered intravenously (tail vein) once a day (Only for Reference)

References

[4] Naim M, et al. J Chem Inf Model, 2007, 47(1), 122-133.

- Collapse

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.73 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Molecular Weight	413.49
Formula	C₂₀H₁₉N₃O.CH₄O₃S
CAS No.	803712-79-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	COC\1=CC(=NC1=C\C2=C(C)C=C(C)[NH]2)C3=CC4=CC=CC=C4[NH]3.C[S](O)(=O)=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00438178	Completed	Drug: Obatoclax mesylate (GX15-070MS)	Hematological Malignancies	Gemin X\|Teva Pharmaceutical Industries	October 2005	Phase 1
NCT00600964	Completed	Drug: GX15-070MS	Chronic Lymphocytic Leukemia	Gemin X\|Teva Pharmaceutical Industries	September 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Pan Bcl-2 Inhibitor

ABT-737 : Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)